H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

Cutting-edge editing techniques are accelerating efforts to create high-yield, resilient varieties of major agricultural products.

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

Twist Bioscience (NASDAQ:TWST – Get Free Report) issued its earnings results on Monday. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0 ...